Bidda Rolin (Denmark)
Novo Nordisk A/S
Cardio-renal Pharmacology
Doctor of Veterinary Medicine, Master of Public Health In vivo pharmacologist/Principal Scientist/Head of Pharmacology Department at Novo Nordisk A/S. Key tasks: Develop and characterise animal models for the individual research projects and support projects with conclusive in vivo data of high standard Secure state of the art in vivo pharmacology within cardiovascular disease. Evaluate and bring forward new target ideas within cardiovascular disease. Key areas of interest; GLP-1 biology and pharmacology, PCSK9 biology and pharmacology Phd and post doc supervisor including collaboration to scientists from academia.

Presenter of 1 Presentation

 Conference Calendar

EFFICACY OF A NOVEL PCSK9 INHIBITORY PEPTIDE ALONE AND IN COMBINATION WITH AN ANTI-ANGPTL3 MONOCLONAL ANTIBODY IN A MOUSE MODEL OF ATHEROSCLEROSIS

Session Name
0090 - PCSK9 – new insights (ID 7)
Session Type
Workshop - Lipids, lipoproteins
Date
Mon, 23.05.2022
Session Time
11:00 - 12:30
Room
Attilio Maseri - Blue room
Presenter
Lecture Time
12:10 - 12:20

Abstract

Background and Aims

Atherosclerosis is the central pathology in cardiovascular disease. This study evaluated the effect of lipid lowering, using a novel peptide inhibiting PCSK9 and a monoclonal antibody against angiopoietin-like 3 (evinacumab), either alone or in combination.

Methods

Transgenic female APOE*3Leiden.CETP mice fed a Western diet for 16 weeks were treated with either evinacumab (EVI) once weekly sc. plus daily injections of vehicle sc or with peptide (PEP) or vehicle (VEH) with daily sc. injections. One group received the combination treatment of EVI and PEP, n=17-18. Statistics: Mann Whitney U-test.

Results

The effects on body weight, plasma lipids and atherosclerotic lesion size and severity were assessed. Treatment with EVI led to a significant decrease in plasma cholesterol (CHOL) and triglycerides (TG) as compared to VEH (-44% and -55%, both p<0.001). PEP significantly decreased CHOL and TG (-69% and -68%, both p<0.001) and the combination of EVI and PEP led to a significant decrease in CHOL and TG (-74% and -81%, both p<0.001). Atherosclerotic lesion size was reduced in all treatment groups compared to VEH: EVI: -72%, PEP -97% and EVI+PEP -98%, all p<0.001. All treatments, led to a significant decrease in the number of lesions (EVI -28%, p=0.024; PEP -79%, p<0.001 and EVI+PEP -81%, p<0.001). Lesion severity was reduced by all treatments as compared to the VEH: EVI -46%, p=0.001, PEP -85%, p<0.001 and EVI+PEP: -85%, p<0.001.

Conclusions

The data show that treatment with EVI and PEP and the combination treatment EVI+PEP strongly reduced cholesterol and triglyceride levels and atherosclerosis development in APOE*3Leiden.CETP mice.

Hide